secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2024-10-28T23:59:59+00:00
Accession:  0001815776-24-000064
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ Therapeutics announces positive Phase 3 data for LNZ100 in China presbyopia trial
--------------------------------------------------------------------------------

- Primary endpoint met: 74% achieved ≥3-line improvement at 3 hours (p<0.0001 vs vehicle).
- Rapid onset: 69% achieved ≥3-line improvement at 30 minutes; 84% achieved ≥2-line improvement.
- Long duration: 30% maintained ≥3-line improvement at 10 hours; 61% achieved ≥2-line improvement.
- No serious treatment-related adverse events observed; well-tolerated in 300-patient study.
- LNZ100 is aceclidine-based eye drop; NDA already accepted by FDA for U.S. market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577624000064/0001815776-24-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577624000064/lenz-20241027.htm
  HTML page:      https://secwatch.observer/filing/0001815776-24-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer